[1]刘 毅,卓 琳,朱 蓓,等.射频消融治疗60岁以上肝细胞癌患者总生存率的meta分析[J].介入放射学杂志,2018,27(04):370-373.
 LIU Yi,ZHUO Lin,ZHU Bei,et al.The overall survival rate of over 60 years old patients with hepatocellular carcinoma after receiving radiofrequency ablation: a meta analysis[J].journal interventional radiology,2018,27(04):370-373.
点击复制

射频消融治疗60岁以上肝细胞癌患者总生存率的meta分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
27
期数:
2018年04期
页码:
370-373
栏目:
临床研究
出版日期:
2018-04-25

文章信息/Info

Title:
The overall survival rate of over 60 years old patients with hepatocellular carcinoma after receiving radiofrequency ablation: a meta analysis
作者:
刘 毅 卓 琳 朱 蓓 何明喻 许 阳 王彤彤 叶静陶 胡 斌 徐继承
Author(s):
LIU Yi ZHUO Lin ZHU Bei HE Mingyu XU Yang WANG Tongtong YE Jingtao HU Bin XU Jicheng
School of Public Health, Xuzhou Medical University, Xuzhou, Jiangsu Province 221004, China
关键词:
【关键词】 老年患者 肝细胞癌 射频消融 总生存率
文献标志码:
A
摘要:
【摘要】 目的 探讨射频消融(RFA)对老年(>60岁)肝细胞癌(HCC)患者总生存率的影响,为老年HCC患者的治疗提供依据。方法 系统收集2000-2016年研究RFA治疗老年与非老年HCC患者总生存率差异的回顾性队列研究,从中提取相关数据;按照NOS量表对纳入文献进行质量评价。结果 共纳入12项回顾性队列研究,包括老年患者1 589例,非老年患者3 336例。Meta分析显示老年患者总生存率低于非老年患者[HR=0.850,95%CI(0.755,0.958),P=0.008];敏感性分析揭示两组总生存率的差异结果可靠,Egger检验显示无明显发表偏倚。结论 老年HCC患者接受RFA治疗总生存率低于非老年患者。

参考文献/References:

[1] Xu XS, Chen W, Miao RC, et al. Survival analysis of hepatocellular carcinoma: a comparison between young patients and aged patients[J]. Chin Med J, 2015, 128: 1793- 1800.
[2] 纪文斌, 肖年军, 罗 英, 等. 甲胎蛋白与异常凝血酶原在鉴别诊断肝细胞癌中的价值[J]. 中华肝胆外科杂志, 2016, 22: 145- 149.
[3] 李 臻, 张恒辉, 韩新巍, 等. 肝细胞癌TACE术后残留病灶的早期诊断现状与进展[J]. 介入放射学杂志, 2015, 24: 1016- 1020.
[4] 陈绍发. CKS1和Cyclin D1在老年肝细胞癌中的表达[J]. 中国老年学杂志, 2013, 33: 4556- 4557.
[5] 含 笑, 吕维富. 经肝动脉化疗栓塞联合射频消融治疗原发性肝癌远期疗效的荟萃分析[J]. 介入放射学杂志, 2013, 22: 387- 391.
[6] 申 权, 薛焕洲, 姜青峰, 等. 老年肝癌患者的射频消融治疗[J]. 肿瘤防治研究, 2009, 36: 431- 442.
[7] Doi K, Beppu T, Ishiko T, et al. Endoscopic radiofrequency ablation in elderly patients with hepatocellular carcinoma[J]. Anticancer Res, 2015, 35: 3033- 3040.
[8] Fujiwara N, Tateishi R, Kondo M, et al. Cause- specific mortality associated with aging in patients with hepatocellular carcinoma undergoing percutaneous radiofrequency ablation[J]. Eur J Gastroenterol Hepatol, 2014, 26: 189- 196.
[9] Takahashi H, Mizuta T, Kawazoe S, et al. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients[J]. Hepatol Res, 2010, 40: 997- 1005.
[10] Lichtenstein MJ, Mulrow CD, Elwood PC. Guidelines for reading case- control studies[J]. J Chronic Dis, 1987, 40: 893- 903.
[11] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time- to- event data into meta- analysis[J]. Trials, 2007, 8: 16.
[12] Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients [J]. J Gastroenterol Hepatol 2010, 25: 403- 407.
[13] Mirici- Cappa F, Gramenzi A, Santi V, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20- year multicentre experience[J]. Gut, 2010, 59: 387- 396.
[14] Nishikawa H, Osaki Y, Iguchi E, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: clinical outcome and safety in elderly patients[J]. J Gastrointestin Liver Dis, 2012, 21: 397- 405.
[15] Kao WY, Chiou YY, Hung HH, et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy[J]. J Clin Gastroenterol, 2012, 46: 62- 70.
[16] Takuma Y, Takabatake H, Morimoto Y, et al. Radiofrequency ablation for hepatocellular carcinoma in elderly patients[J]. Nihon Shokakibyo Gakkai Zasshi, 2013, 110: 403- 411.
[17] Liu PH, Hsu CY, Lee YH, et al. Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis[J]. Medicine(Baltimore), 2014, 93: e264.
[18] Yamazaki H, Tsuji K, Nagai K, et al. Efficacy and long- term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma[J]. Hepatol Res, 2014, 44: 721- 734.
[19] Zhang F, Wu G, Sun H, et al. Radiofrequency ablation of hepatocellular carcinoma in elderly patients fitting the Milan criteria: a single centre with 13 years experience[J]. Int J Hyperthermia, 2014, 30: 471- 479.
[20] 严 昆, 陈敏华, 杨 薇, 等. 肝细胞肝癌射频消融治疗远期疗效分析[J]. 中华消化杂志, 2006, 28: 556- 558.
[21] 尹珊珊, 王艳滨, 杨 薇, 等. 高龄原发性肝癌射频治疗疗效分析[J]. 中华老年多器官疾病杂志, 2005, 4: 191- 195.
[22] 姚雪松, 闫 东, 曾辉英, 等. TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J]. 介入放射学杂志, 2014, 23: 769- 771.
[23] 陈 璐, 张 倜, 崔云龙, 等. 多发性肝细胞癌113例患者临床治疗的回顾性分析[J]. 中华肝胆外科杂志, 2014, 20: 15- 19.
[24] Taniai N, Yoshida H, Yoshioka M, et al. Surgical outcomes and prognostic factors in elderly patients(75 years or older) with hepatocellular carcinoma who underwent hepatectomy[J]. J Nippon Med Sch, 2013, 80: 426- 432.
[25] Ishikawa T. Radiofrequency ablation is justified for elderly patients with hepatocellular carcinoma[J]. Hepatol Res, 2010, 40: 954- 955.

相似文献/References:

[1]叶强.PEIT治疗肝脏恶性肿瘤[J].介入放射学杂志,1998,(01):24.
[2]叶强.肝脏肿瘤的经皮穿刺治疗:技术现状[J].介入放射学杂志,1998,(01):16.
[3]HondaN,Guo Q,Uchida H,等.经皮穿刺灼热生理盐水注射治疗肝癌——一个替代酒精注射的方法[J].介入放射学杂志,1995,(02):121.
[4]刘鹏芝,韩金红,赵凤珍,等.肝癌介入治疗中导管和导丝系列的清洗和消毒[J].介入放射学杂志,1996,(01):50.
[5]罗正益,李兴跃.肝脏疾病的血管造影诊断[J].介入放射学杂志,1996,(01):26.
[6]罗正益,曾炳生,郝春志,等.小肝癌CT和血管造影诊断——自内向外顺序染色征象的意义[J].介入放射学杂志,1996,(01):30.
[7]张大海,顾伟中,叶强.肝细胞癌的非手术治疗[J].介入放射学杂志,2000,(02):122.
[8]张璐西,施海彬,刘 圣,等.ACE联合索拉非尼治疗BCLC C期肝细胞癌20例疗效分析[J].介入放射学杂志,2014,(11):954.
 ZHANG Lu xi,SHI Hai bin,LIU Sheng,et al.Transarterial chemoembolization combined with sorafenib for hepatocellular carcinoma in BCLC C stage: clinical analysis of 20 cases[J].journal interventional radiology,2014,(04):954.
[9]赵 丹,梁 斌,王 勇,等.肝癌化疗栓塞后溶瘤综合征1例 [J].介入放射学杂志,2018,27(05):461.
 ZHAO Dan,LIANG Bin,WANG Yong,et al.Tumor lysis syndrome after transcatheter arterial chemoembolization: report of one case[J].journal interventional radiology,2018,27(04):461.
[10]张 雯,李 说,颜志平,等.植入性门静脉主干癌栓兔模型建立及评估[J].介入放射学杂志,2015,(09):801.
 ZHANG Wen,LI Shuo,YAN Zhi- ping,et al.Implanted main portal venous tumor thrombus model in experimental rabbits: its establishment and evaluation[J].journal interventional radiology,2015,(04):801.

备注/Memo

备注/Memo:
(收稿日期:2016-12-12)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2018-04-16